Skip to main content
Redox Biology logoLink to Redox Biology
. 2022 Apr 14;52:102315. doi: 10.1016/j.redox.2022.102315

Corrigendum to “Mfn2-mediated mitochondrial fusion alleviates doxorubicin-induced cardiotoxicity with enhancing its anticancer activity through metabolic switch” [Redox Biol. 52 (2022) 1–16/102311]

Mingge Ding a,∗∗,1, Rui Shi a,b,1, Shuli Cheng c,1, Man Li b,d, Dema De a,b, Chaoyang Liu b, Xiaoming Gu b, Juan Li b, Shumiao Zhang b, Min Jia b, Rong Fan b, Jianming Pei b,∗∗∗, Feng Fu b,
PMCID: PMC9108085  PMID: 35431146

After publication of the original article [1], it came to the authors' attention that one important piece of information was lost for affiliation “b Department of Physiology and Pathophysiology, National Key Discipline of Cell Biology, China”. It should be “b Department of Physiology and Pathophysiology, National Key Discipline of Cell Biology, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China”. The affiliations are correct in this corrigendum.

Contributor Information

Mingge Ding, Email: dingmingge@xjtu.edu.cn.

Jianming Pei, Email: jmpei8@fmmu.edu.cn.

Feng Fu, Email: fufeng048@126.com.

References

  • 1.Ding M., Shi R., Cheng S., Li M., De D., Liu C., Gu X., Li J., Zhang S., Jia M., Fan R., Pei J., Fu F. Mfn2-mediated mitochondrial fusion alleviates doxorubicin-induced cardiotoxicity with enhancing its anticancer activity through metabolic switch. Redox Biol. 2022;52 doi: 10.1016/j.redox.2022.102311. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Redox Biology are provided here courtesy of Elsevier

RESOURCES